Clinical trials: Cerebral Vascular Disorder
Myocardial Infarction, Segment Elevation Myocardial Infarction (STEMI)
A 30 Day Study to Evaluate Efficacy and Safety of Pre-hospital vs. In-hospital Initiation of Ticagrelor Therapy in STEMI Patients Planned for Percutaneous Coronary Intervention (PCI)
The aim of this study is to determine whether initiation of ticagrelor as early as in the ambulance setting leads to a rapid reperfusion of the infarct-related artery therefore facilitating the Percutaneous Coronary Intervention…
- Trial name
- ATLANTIC (NCT01347580)
- Testing
- Ticagrelor
- Where
- 96 sites in Algeria, Australia and 11 more
- Volunteers
- 1,875 people
- Sponsor
- AstraZeneca
Stroke
An Open Label, Phase 1b, Ascending Dose Study of DM199
This is a Phase 1B study to assess the safety, tolerability and pharmacokinetics of DM199 in healthy volunteers. The study will be consist of two parts: Part A will focus on intravenous dosing and Part B will directly compare…
- Trial name
- NCT02868996
- Testing
- Recombinant human tissue kallikrein
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- DiaMedica Therapeutics Inc
Acute Ischemic Stroke
HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke.
This study plans to enroll a total of 208 patients with Acute Ischemic Stroke (AIS) who present within 4.5 to 24 hours of symptom onset and meet the specified imaging criteria.
- Trial name
- NCT07233070
- Testing
- HRS-7450 Injection
- Where
- 2 sites in China
- Volunteers
- 210 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Chronic Ischemic Stroke
Study of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Ischemic Stroke
Controlled study of stereotactic, intracranial injection of SB623 cells in patients with fixed motor deficits from ischemic stroke
- Trial name
- ACTIsSIMA (NCT02448641)
- Testing
- SB623 Implant (2.5M), SB623 Implant (5.0M)
- Where
- 65 sites in United States
- Volunteers
- 163 people
- Sponsor
- SanBio, Inc.
Acute Ischemic Stroke
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
Primary objective: To demonstrate superiority of enoxaparin 40 mg sc qd in the prevention of VTE compared to UFH (unfractionated heparin) 5000 U sc q12 hours given for 10 ± 4 days following acute ischemic stroke.
- Trial name
- NCT00077805
- Testing
- Enoxaparin sodium
- Where
- 15 sites in United States, Australia and 13 more
- Sponsor
- Sanofi
Intracranial Aneurysm, Brain Arterial Disease
Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform
BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices.
- Conditions
- Intracranial Aneurysm, Brain Arterial Disease, Acute Ischemic Stroke, Peripheral Vascular Diseases
- Trial name
- EVIDENCE (NCT04927156)
- Testing
- BALT medical devices
- Where
- 12 sites in France, Germany and 1 more
- Volunteers
- 10,000 people
- Sponsor
- Balt Extrusion
Acute Ischemic Stroke
A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）
The purpose of this study is to assess the efficacy and safety of recombinant human tissue plasminogen kinase derivatives for injection and alteplase in the treatment of patients with acute ischemic stroke within 4.5 hours.
- Trial name
- NCT05295173
- Testing
- Injection of recombinant human tissue plasminogen kinase derivatives, Recombinant human tissue plasminogen activator
- Where
- 78 sites in China
- Volunteers
- 1,412 people
- Sponsor
- Angde Biotech Pharmaceutical Co., Ltd.
Cerebrovascular Accident
A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients
This study will investigate the effects of a potential neuroprotectant compound, YM872, in the treatment of acute ischemic stroke.
- Trial name
- NCT00044070
- Testing
- YM872 (zonampanel)
- Where
- 89 sites in United States, Austria and 4 more
- Sponsor
- Astellas Pharma Inc
Acute Coronary Syndrome, Stroke
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SP-8008
This is a single-centre, double-blind, randomised, placebo-controlled single oral-dose escalation study in healthy male subjects. It is planned to enrol approximately 48 subjects into up to 6 planned dose level cohorts.
- Trial name
- NCT04770194
- Testing
- SP-8008 Prototype Capsule A, SP-8008 Prototype Capsule B
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Carotid Artery Stenosis, Hypercholesterolemia
Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects
The purpose of this study is to examine the changes in the carotid artery when subjects receive high or low doses of rosuvastatin.
- Trial name
- NCT00654394
- Testing
- Rosuvastatin
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Injuries, Acute Brain, Severe Trauma Brain Injury (sTBI)
Bioavailability of Medium Chain Triglycerides (MCTs) in Comatose Patients With Acute Brain Injury (ABI)
This study will be targeting patients suffering from acute brain injury (ABI), including those with severe trauma brain injury (sTBI) and those with aneurysmal sub arachnoid hemorrhage (aSAH).
- Conditions
- Injuries, Acute Brain, Severe Trauma Brain Injury (sTBI), Subarachnoid Hemorrhage, Aneurysmal
- Trial name
- MCTs and ABI (NCT02716532)
- Testing
- Peptamen AF
- Where
- Switzerland
- Volunteers
- 17 people
- Sponsor
- Société des Produits Nestlé (SPN)
Aneurysmal Subarachnoid Hemorrhage
Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy Subjects
This is a Phase 1, single center, randomized, two-period crossover study in healthy male and female subjects designed to evaluate the relative bioavailability (BA) and safety at steady state of two formulations of nimodipine: GTX…
- Trial name
- NCT05418348
- Testing
- GTX-104, Nimodipine Capsules
- Where
- Canada
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Grace Therapeutics Inc.
Carotid Artery Diseases
Silk Road Medical First in Man Study - Neuroprotection During Carotid Stenting and Angioplasty
Cerebral embolization during carotid artery stenting (CAS) can often precipitate severe adverse neurological effects. Most major clinical studies of CAS have used distal filters for cerebral protection and have compared the…
- Trial name
- PROOF (NCT01264419)
- Testing
- Silk Road Embolic Protection System
- Where
- Germany
- Volunteers
- 75 people
- Sponsor
- Silk Road Medical
Hydrocephalus, Hydrocephalus in Children
Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve
Post-Market Clinical Follow-up Registry of Patients with CODMAN CERTAS Plus Programmable Valves.
- Conditions
- Hydrocephalus, Hydrocephalus in Children, NPH (Normal Pressure Hydrocephalus), IIH - Idiopathic Intracranial Hypertension
- Trial name
- NCT05397106
- Testing
- CODMAN CERTAS Plus Programmable Valve
- Where
- 9 sites in Belgium, Germany and 2 more
- Volunteers
- 160 people
- Sponsor
- Integra LifeSciences Corporation
Cerebrovascular Accident (CVA), Stroke
Evaluating the Indego Exoskeleton for Persons With Hemiplegia Due to CVA
The purpose of this study is to evaluate the safety and effectiveness of the Indego exoskeleton as a gait training tool for individuals with hemiplegia due to Cerebrovascular Accident (CVA).
- Conditions
- Cerebrovascular Accident (CVA), Stroke, Hemiplegia
- Trial name
- NCT03054064
- Testing
- Indego Exoskeleton
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Parker Hannifin Corporation
Acute Ischemic Stroke (AIS)
A Phase I Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of AAPB for Injection
This is a Phase I clinical to evaluate the safety and tolerability of single and multiple intravenous infusions of AAPB at different doses over 7 consecutive days.
- Trial name
- AAPB (NCT06679998)
- Testing
- Single dose, AAPB by injection, intravenous drip., Multiple dosing, AAPB for injection, intravenous drip
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
Stroke, Patent Foramen Ovale
Comparing PFO Outcomes of the Occlutech Flex II PFO Occluder to Standard of Care PFO Occlusion
The objective of this study is to investigate whether percutaneous PFO closure with the Occlutech Flex II PFO Occluder is non-inferior to the AMPLATZER™ PFO Occluder and Gore® Cardioform Septal Occluder in closure of the PFO…
- Conditions
- Stroke, Patent Foramen Ovale, PFO
- Trial name
- OCCLUFLEX (NCT05069558)
- Testing
- Investigational PFO Closure Device, Standard of Care PFO Closure Device
- Where
- 48 sites in United States, Canada and 6 more
- Volunteers
- 450 people
- Sponsor
- Occlutech International AB
Acute Ischemic Stroke From Large Vessel Occlusion
A Randomized, Concurrent Controlled Trial to Assess the Safety and Effectiveness of the Separator 3D as a Component of the Penumbra System in the Revascularization of Large Vessel Occlusion in Acute Ischemic Stroke
This is a prospective, randomized, single blind, concurrent controlled, multi-center study. Patients presenting with symptoms of acute ischemic stroke who have evidence of a large vessel (2.5mm or greater in diameter) occlusion…
- Trial name
- NCT01584609
- Testing
- Penumbra System with Separator 3D, Penumbra System alone
- Where
- 8 sites in United States
- Volunteers
- 198 people
- Sponsor
- Penumbra Inc.
CVA (Cerebrovascular Accident)
Wearable Robotic Functional Assistance for Stroke Rehabilitation
This study aims to evaluate the effectiveness of using the myomo e100 wearable robotic rehabilitation system for increasing functional independence and long term rehabilitation of chronic stroke victims with a hemiparetic upper…
- Trial name
- NCT00396708
- Testing
- myomo e100 neurorobotic elbow brace
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Myomo
Fabry Disease
A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease
People with Fabry Disease have an alteration in their genetic material (DNA) which causes a deficiency of the alpha-galactosidase A enzyme.
- Trial name
- NCT00081497
- Testing
- agalsidase beta
- Where
- 25 sites in United States, Canada and 4 more
- Volunteers
- 67 people
- Sponsor
- Genzyme, a Sanofi Company